EcoR1 Capital — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Co-investorsSamsara BioCapitalARCH VentureARCH Venture PartnersPolaris Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.